Virtus LifeSci Biotech Clinical Trials ETF
Investment Overview
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.
Investment Partner
LifeSci Index Partners, LLC
LifeSci Index Partners, LLC is a New York-based index provider of healthcare-based stock market indices. The LifeSci team is comprised of investment professionals with experience in biotechnology equity research, in organic chemistry research in academia, and at pharmaceutical and biotechnology companies.
LifeSci Index Partners, LLC is the index provider to the Fund. The portfolio managers are affiliated with Virtus ETF Advisers, LLC, the Fund's adviser.
Investment Professionals
Matthew B. Brown
Chief Operating Officer and Portfolio Manager, Virtus ETF Advisers LLC
Industry start date: 1999
Start date as fund Portfolio Manager: 2017
Seth Kadushin
Portfolio Manager, Virtus ETF Advisers LLC
Industry start date: 1988
Start date as fund Portfolio Manager: 2017
Key Features
High-Growth Potential
One of the most dynamic stock sectors, covering companies that design drugs, from entrepreneurial start-ups to global giants
Pure, Targeted Exposure
Passively invests solely in firms with promising drugs in clinical human trials that have not yet been approved by the FDA or gone into production
Equally Weighted
Equal stock weightings, at the time of semi-annual index rebalance, help ensure even relatively small firms with major breakthroughs can have meaningful impacts on returns
Top Holdings (% Fund)
| Security | |
|---|---|
| AMYRIS INC | |
| PROTHENA CORP PLC | |
| RUBIUS THERAPEUTICS INC | |
| BIOCRYST PHARMACEUTICALS INC | |
| VERASTEM INC | |
| I-MAB-SPONSORED ADR | |
| DYNAVAX TECHNOLOGIES CORP | |
| MORPHIC HOLDING INC | |
| HUMANIGEN INC | |
| CELLDEX THERAPEUTICS INC |
Does not include cash/cash equivalents.
Performance
Performance data quoted represents past results. Past performance is no guarantee of future results and current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate, so your shares, when redeemed, may be worth more or less than their original cost.
Sales Charge and Expenses
Fees & Expenses
| Total Expense Ratio | 0.79 |
Premium/Discount
| Number of Days Fund has Traded at a: | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Discount | Premium | |||||||||
| Period | Less than -2% | -1.51% to -2.00% | -1.01% to -1.50% | -0.51% to -1.00% | -0.01% to -0.50% | 0.00% to 0.50% | 0.51% to 1.00% | 1.01% to 1.50% | 1.51% to 2.00% | Greater than 2% |
| 2019-Q2: 4/1/2019 through 6/28/2019 | 0 | 0 | 0 | 0 | 61 | 2 | 0 | 0 | 0 | 0 |
| 2019-Q3: 7/1/2019 through 9/30/2019 | 0 | 0 | 0 | 0 | 61 | 3 | 0 | 0 | 0 | 0 |
| 2019-Q4: 10/1/2019 through 12/31/2019 | 0 | 0 | 0 | 0 | 48 | 16 | 0 | 0 | 0 | 0 |
| 2020-Q1: 1/2/2020 through 3/31/2020 | 0 | 1 | 0 | 2 | 41 | 18 | 0 | 0 | 0 | 0 |
| 2020-Q2: 4/1/2020 through 6/30/2020 | 0 | 0 | 0 | 0 | 34 | 29 | 0 | 0 | 0 | 0 |
| 2020-Q3: 7/1/2020 through 9/30/2020 | 0 | 0 | 0 | 0 | 41 | 23 | 0 | 0 | 0 | 0 |
| 2020-Q4: 10/1/2020 through 12/31/2020 | 0 | 0 | 0 | 0 | 52 | 12 | 0 | 0 | 0 | 0 |
| 2021-Q1: 1/4/2021 through 3/31/2021 | 0 | 0 | 0 | 0 | 40 | 21 | 0 | 0 | 0 | 0 |
Risk Considerations
Marketing Materials
Financial Materials
Please consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. The prospectus contains this and other information about the Fund. Contact us at 1-888-383-0553 or visit www.virtus.com for a copy of the Fund's prospectus. Read the prospectus carefully before you invest or send money.
Performance data quoted represents past results. Past performance is no guarantee of future results and current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate so your shares, when redeemed, may be worth more or less than their original cost.
Closing Price: The Closing Price is the price of the last reported trade on the fund's primary exchange. If there has been no reported trade for a particular date, the Closing Price represents the 4PM Bid/Offer Midpoint.
4PM Bid/Offer Midpoint: The midpoint between the highest bid and the lowest offer on the listing exchange, as of the time that the Fund's NAV is calculated (usually 4:00pm Eastern Time).
Premium/Discount: The amount the Fund is trading above or below the reported NAV (based on 4PM Bid/Offer Midpoint).
The Fund is an exchange-traded fund (“ETF”). The “net asset value” (NAV) of the Fund is determined at the close of each business day, and represents the dollar value of one share of the Fund; it is calculated by taking the total assets of the Fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV of the Fund is not necessarily the same as its intraday trading value. Fund investors should not expect to buy or sell shares at NAV because shares of ETFs such as the Fund are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Thus, shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns.
NAV returns are calculated using the Fund’s daily 4:00 p.m. NAV, and include the reinvestment of all dividends and other distributions (reinvested at the Fund's NAV on distribution ex-date). Market price returns are calculated using the 4:00 pm midpoint between the bid and offer, and include the reinvestment of all dividends and other distributions (reinvested at the 4:00pm bid/offer midpoint on distribution ex-date). Market price returns do not represent the return you would receive if you traded at other times.
Returns for periods of less than one year are cumulative total returns.
Not insured by FDIC/NCUSIF or any federal government agency. No bank guarantee. Not a deposit. May lose value.